drugset / Trial / NCT02871791
Palbociclib With Everolimus + Exemestane In BC
NaSingle-groupOpen-labelTreatment
Summary
This research study is studying a combination of targeted therapy and hormonal therapy as a possible treatment for breast cancer that has spread to other places in the body and is hormone receptor positive (HR+) and HER2-negative. The names of the study interventions involved in this study are: * Palbociclib * Everolimus * Exemestane
Timeline
- Start
- 2016-08-24
- Primary completion
- 2020-12-03
- Completion
- 2021-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Everolimus | Small molecule | 5 mg | Oral |
| Subject | Exemestane | Small molecule | 25 mg | Oral |
| Subject | Palbociclib | Small molecule | 100 mg | Oral |